Aldosterone target organ protection by eplerenone
- PMID: 15134822
- DOI: 10.1016/j.mce.2003.10.047
Aldosterone target organ protection by eplerenone
Abstract
The classical mineralocorticoid effect of aldosterone on unidirectional transepithelial sodium transport in the kidney was long thought to be the predominant effect of this hormone. However, there is convincing evidence for additional extrarenal actions of aldosterone that are mediated via activation of mineralocorticoid receptors (MRs) in the heart, vasculature and brain. It is now postulated that many of the detrimental effects of aldosterone are mediated through MR activation in these nonclassical target organs. The selective aldosterone blocker, eplerenone (Inspra), is under development for human therapeutic use for treatment of hypertension and heart failure post-myocardial infarction (MI). Clinical and preclinical studies have linked elevated aldosterone to hypertension, left ventricular and vascular remodeling, cardiac, renal, and cerebral vascular inflammation and injury, and increased risk of mortality in heart failure patients. Multiple studies in experimental models of hypertension and heart failure demonstrate that selective blockade of aldosterone by eplerenone effectively preserves cardiac function, attenuates maladaptive left ventricular remodeling and tissue and vascular injury in part by reducing vascular inflammation in aldosterone target organs.
Similar articles
-
Blocking aldosterone in heart failure.Ther Adv Cardiovasc Dis. 2009 Oct;3(5):379-85. doi: 10.1177/1753944709341300. Epub 2009 Aug 6. Ther Adv Cardiovasc Dis. 2009. PMID: 19661156 Review.
-
Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.Heart Dis. 2003 Sep-Oct;5(5):354-63. doi: 10.1097/01.hdx.0000089783.30450.cb. Heart Dis. 2003. PMID: 14503934 Review.
-
Aldosterone inhibition and cardiovascular protection: more important than it once appeared.Cardiovasc Drugs Ther. 2010 Aug;24(4):345-50. doi: 10.1007/s10557-010-6256-6. Cardiovasc Drugs Ther. 2010. PMID: 20676926
-
New treatment option for heart failure patients: eplerenone.J Cardiovasc Nurs. 2004 Nov-Dec;19(6):390-5. doi: 10.1097/00005082-200411000-00010. J Cardiovasc Nurs. 2004. PMID: 15529060 Review.
-
Review article: eplerenone: an underused medication?J Cardiovasc Pharmacol Ther. 2010 Dec;15(4):318-25. doi: 10.1177/1074248410371946. Epub 2010 Sep 27. J Cardiovasc Pharmacol Ther. 2010. PMID: 20876342 Review.
Cited by
-
Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone.Biomed Res Int. 2015;2015:652738. doi: 10.1155/2015/652738. Epub 2015 Sep 10. Biomed Res Int. 2015. PMID: 26448944 Free PMC article. Review.
-
Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction.Core Evid. 2005;1(2):125-41. Epub 2005 Jun 30. Core Evid. 2005. PMID: 22500149 Free PMC article.
-
Aldosterone stimulates superoxide production in macula densa cells.Am J Physiol Renal Physiol. 2011 Sep;301(3):F529-35. doi: 10.1152/ajprenal.00596.2010. Epub 2011 Jan 26. Am J Physiol Renal Physiol. 2011. PMID: 21270097 Free PMC article.
-
Mineralocorticoid receptor antagonists and heart failure with preserved ejection fraction: current understanding and future prospects.Heart Fail Rev. 2025 Jan;30(1):191-208. doi: 10.1007/s10741-024-10455-1. Epub 2024 Oct 17. Heart Fail Rev. 2025. PMID: 39414721 Review.
-
Interaction between nitric oxide and superoxide in the macula densa in aldosterone-induced alterations of tubuloglomerular feedback.Am J Physiol Renal Physiol. 2013 Feb 1;304(3):F326-32. doi: 10.1152/ajprenal.00501.2012. Epub 2012 Dec 5. Am J Physiol Renal Physiol. 2013. PMID: 23220724 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical